GSK submits Rezonic NDA

GlaxoSmithKline (LSE:GSK; NYSE:GSK) said it submitted an NDA last week for an IV and an oral formulation of Rezonic casopitant to prevent chemotherapy-induced nausea and vomiting (CINV) as an add-on t...